Today: 20 May 2026
Browse Category

NASDAQ:MIST 12 December 2025 - 15 December 2025

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

Milestone Pharmaceuticals (MIST) Stock: FDA Approval of CARDAMYST, Launch Timeline, and Analyst Forecasts (Dec. 15, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST (etripamil) nasal spray for adults with paroxysmal supraventricular tachycardia, marking the first new U.S. PSVT treatment in over 30 years. The company targets retail availability in Q1 2026. Shares showed sharp volatility after the announcement. Milestone scheduled an investor call for December 15 to discuss launch plans.
15 December 2025
·
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals said late Friday the FDA approved CARDAMYST (etripamil) as the first self-administered nasal spray for PSVT. MIST shares closed down 18.3% at $2.41 after volatile trading and heavy volume, but rebounded modestly after hours. CARDAMYST is expected in pharmacies in Q1 2026. In a Phase 3 trial, 64% of patients converted to normal rhythm within 30 minutes, compared to 31% on placebo.
14 December 2025
··
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

The FDA approved Milestone Pharmaceuticals’ CARDAMYST nasal spray for on-demand treatment of PSVT in adults, marking the first new U.S. therapy for the condition in over 30 years. The company expects CARDAMYST in pharmacies by Q1 2026. MIST shares were volatile ahead of the decision and ended the week lower despite the approval.
13 December 2025
··
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals shares closed at $2.95 on Dec. 11, up 10.49% with about 7.54 million shares traded, ahead of an FDA decision on CARDAMYST nasal spray for PSVT due Dec. 13. The stock traded around $2.98 pre-market Dec. 12, rebounding from a 52-week low of $0.625 after an FDA rejection earlier in 2025 and subsequent resubmission.
12 December 2025
·

Stock Market Today

  • Target Q1 CY2026 Earnings Beat Expectations with 6.7% Sales Growth
    May 20, 2026, 8:18 AM EDT. Target (NYSE:TGT) reported Q1 CY2026 revenue of $25.44 billion, 6.7% higher year on year and beating analyst estimates by 3.4%. Adjusted earnings per share (EPS) came in at $1.71, 17.3% above consensus. The company forecasts 4% net sales growth for full year 2026, up 2 percentage points from prior guidance. Operating margin declined to 4.5% from 6.2% a year ago, while free cash flow loss narrowed to $319 million. Same-store sales rose 5.6% year on year, reversing a prior decline. CEO Michael Fiddelke highlighted stronger-than-expected results and positive response to Target's strategic focus. With a $57.79 billion market capitalization, Target faces growth challenges amid market saturation but aims to leverage scale and innovation moving forward.

Latest articles

Hasbro’s Magic Keeps Wall Street Looking at the Stock

Hasbro’s Magic Keeps Wall Street Looking at the Stock

20 May 2026
Hasbro reported first-quarter revenue of $1 billion, beating estimates, with adjusted earnings per share at $1.47. Magic: The Gathering drove a 26% jump in Wizards and Digital Gaming revenue. Operating profit rose 58% to $270 million. The company maintained its 2026 outlook but cited ongoing risks from cyber costs and tariffs.
VF Stock Moves Higher After Company Says Growth Is Returning

VF Stock Moves Higher After Company Says Growth Is Returning

20 May 2026
VF Corp reported its first full-year revenue growth in three years, with fourth-quarter revenue rising to $2.17 billion, beating Wall Street estimates. Adjusted earnings were break-even. The company reinstated annual guidance for fiscal 2027 and kept its dividend at 9 cents a share. Shares rose 8.2% premarket to $18.11.
Lowe’s Beat Wall Street. Why Investors Still Sold the Stock

Lowe’s Beat Wall Street. Why Investors Still Sold the Stock

20 May 2026
Lowe’s posted quarterly sales of $23.08 billion and adjusted earnings of $3.03 per share, both above analyst estimates, but shares fell 3% premarket as investors focused on weak U.S. housing trends. Comparable sales rose 0.6%, driven by online growth and contractor demand. The company kept its 2026 outlook unchanged. U.S. mortgage rates climbed to 6.56% last week, weighing on home sales and renovations.
Go toTop